Product image of Ibiron (Abiraterone Acetate) supplied by GNH India

Ibiron

Active Ingredient:
Abiraterone Acetate
Origin:
EU

Ibiron (Abiraterone Acetate)

Abiraterone acetate, the active ingredient in Ibiron, is an androgen biosynthesis inhibitor presented as an oral tablet for oral use. It treats metastatic castration‑resistant prostate cancer in men who have progressed despite androgen deprivation therapy.

GNH India supplies Ibiron as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Viatris Medical

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ibiron is an androgen biosynthesis inhibitor used in the management of prostate cancer that has become resistant to standard hormonal therapy.

  • Metastatic castration‑resistant prostate cancer: improves overall survival and delays disease progression when combined with prednisone.
  • Castration‑resistant prostate cancer: reduces tumor growth by lowering systemic and intratumoral androgen levels.
  • Advanced prostate cancer: used after progression on androgen deprivation therapy to extend clinical benefit.

How It Works

  • Abiraterone acetate selectively inhibits the CYP17A1 enzyme, a key catalyst in androgen biosynthesis within the testes, adrenal glands and prostate tumor tissue. By blocking this enzyme, the drug markedly reduces circulating and intratumoral testosterone and other androgen precursors, thereby limiting the hormonal stimulation that drives prostate cancer cell proliferation and survival.

Side Effects

Ibiron may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Hypertension: elevated blood pressure requiring monitoring.
  • Nausea: mild to moderate gastrointestinal upset.
  • Edema: swelling of extremities due to fluid retention.
  • Hot flashes: transient episodes of warmth and sweating.

Serious or Rare Side Effects

  • Liver enzyme elevation: potential hepatotoxicity needing periodic liver function tests.
  • Adrenal insufficiency: reduced cortisol production that may cause fatigue and hypotension.
  • Severe hypertension or cardiac failure: may require medical intervention.
  • Thromboembolic events: rare blood clot formation.
  • Interstitial lung disease: uncommon respiratory complications.

Precautions & Warnings

Before initiating Ibiron, clinicians should assess patient-specific risk factors and monitor relevant parameters.

  • Monitor blood pressure: check regularly to detect hypertension.
  • Monitor potassium and electrolyte levels: watch for hypokalemia and fluid imbalance.
  • Assess liver function: perform baseline and periodic liver enzyme tests.
  • Avoid concomitant strong CYP3A4 inducers: may reduce drug efficacy.
  • Use with low‑dose prednisone: mitigates mineralocorticoid‑related side effects.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Ibiron can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may markedly decrease abiraterone exposure.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase drug levels and toxicity.
  • Mineralocorticoid agonists (e.g., fludrocortisone): may exacerbate fluid retention and hypertension.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: may require dose adjustments due to blood‑pressure changes.

  • Anticoagulants: monitor for altered bleeding risk.
  • CYP2D6 substrates: observe for potential pharmacokinetic alterations.

Frequently Asked Questions

Ibiron contains abiraterone acetate and is indicated for the treatment of metastatic castration‑resistant prostate cancer in men, typically after disease progression on androgen deprivation therapy. It forms part of hormone‑based therapy aimed at slowing tumor growth.

Abiraterone acetate blocks the CYP17A1 enzyme, which is essential for androgen production in the testes, adrenal glands and prostate tumor cells. Inhibiting this enzyme reduces circulating and intratumoral testosterone, depriving prostate cancer cells of the hormones that drive their growth.

The prescribed dose is determined by the treating physician based on the patient’s clinical status, concurrent medications and laboratory results. The prescriber selects the appropriate strength and regimen in line with approved labeling and local clinical guidelines.

Abiraterone acetate is contraindicated during pregnancy and is not recommended for breastfeeding because it may affect fetal development and can be excreted in breast milk. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after the last dose.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibiron (abiraterone acetate) differs from agents such as enzalutamide in that it inhibits androgen synthesis rather than blocking the androgen receptor. Both are approved for metastatic castration‑resistant prostate cancer, but the choice depends on prior therapy, side‑effect profile, drug‑drug interactions and individual patient comorbidities.

Ibiron should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not keep it in a bathroom or near heat sources, and keep the container tightly closed when not in use.

Ibiron is taken orally, usually once daily, with food to enhance absorption. It is commonly prescribed together with a low dose of prednisone to mitigate mineralocorticoid‑related side effects. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include severe hypertension, liver enzyme elevation, adrenal insufficiency, cardiac failure and rare thromboembolic events. Regular monitoring of blood pressure, liver function, electrolytes and cardiac status is essential, and any concerning symptoms should prompt immediate medical evaluation.

Ibiron is not recommended for patients with uncontrolled hypertension, active liver disease, severe cardiac conditions, or those receiving strong CYP3A4 inducers or inhibitors without careful monitoring. It is also contraindicated in women who are pregnant or breastfeeding and in individuals with known hypersensitivity to abiraterone acetate or any excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Abiraterone Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT